Aimmune Therapeutics, Inc. (NASDAQ:AIMT) CEO Stephen George Dilly sold 80,110 shares of Aimmune Therapeutics stock in a transaction on Wednesday, October 4th. The shares were sold at an average price of $26.23, for a total transaction of $2,101,285.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Stephen George Dilly also recently made the following trade(s):

  • On Friday, October 6th, Stephen George Dilly sold 4,047 shares of Aimmune Therapeutics stock. The shares were sold at an average price of $26.31, for a total transaction of $106,476.57.
  • On Thursday, October 5th, Stephen George Dilly sold 14,689 shares of Aimmune Therapeutics stock. The shares were sold at an average price of $26.24, for a total transaction of $385,439.36.
  • On Monday, September 25th, Stephen George Dilly sold 100,000 shares of Aimmune Therapeutics stock. The shares were sold at an average price of $25.01, for a total transaction of $2,501,000.00.
  • On Wednesday, July 26th, Stephen George Dilly sold 50,000 shares of Aimmune Therapeutics stock. The shares were sold at an average price of $21.46, for a total transaction of $1,073,000.00.

Aimmune Therapeutics, Inc. (NASDAQ AIMT) opened at 25.36 on Friday. The stock’s 50 day moving average is $24.34 and its 200-day moving average is $24.34. Aimmune Therapeutics, Inc. has a one year low of $14.87 and a one year high of $27.31. The firm’s market capitalization is $1.28 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). On average, analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/10/08/stephen-george-dilly-sells-80110-shares-of-aimmune-therapeutics-inc-aimt-stock.html.

Several equities research analysts have weighed in on the stock. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, July 27th. Wedbush reaffirmed an “outperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research note on Monday, July 24th. BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. ValuEngine raised shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, June 13th. Finally, Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research note on Thursday, July 27th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $40.00.

Several institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its stake in shares of Aimmune Therapeutics by 20.3% in the 2nd quarter. California State Teachers Retirement System now owns 62,315 shares of the biotechnology company’s stock worth $1,281,000 after acquiring an additional 10,500 shares in the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Aimmune Therapeutics by 31.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 27,694 shares of the biotechnology company’s stock worth $570,000 after acquiring an additional 6,690 shares in the last quarter. State Street Corp increased its stake in shares of Aimmune Therapeutics by 26.6% in the 2nd quarter. State Street Corp now owns 1,087,320 shares of the biotechnology company’s stock worth $22,351,000 after acquiring an additional 228,429 shares in the last quarter. Palo Alto Investors LLC increased its stake in shares of Aimmune Therapeutics by 9.9% in the 2nd quarter. Palo Alto Investors LLC now owns 1,289,719 shares of the biotechnology company’s stock worth $26,517,000 after acquiring an additional 116,221 shares in the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in shares of Aimmune Therapeutics by 139.9% in the 2nd quarter. Goldman Sachs Group Inc. now owns 227,377 shares of the biotechnology company’s stock worth $4,675,000 after acquiring an additional 132,603 shares in the last quarter. Institutional investors own 72.90% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Insider Buying and Selling by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.